Literature DB >> 31346706

[Antisynthetase syndromes].

Jutta Bauhammer1, Christoph Fiehn2.   

Abstract

Antisynthetase syndromes (ASS) are rare autoimmune diseases. Characteristic is the presence of at least one of the three main symptoms myositis, interstitial lung disease (ILD) and arthritis with possible accompanying symptoms, such as mechanic's hands and feet, Raynaud's disease and/or fever in combination with detection of an aminoacyl-tRNA synthetase antibody in peripheral blood. In addition to myositis, ILD is a frequent and often predominant organ involvement and is responsible for morbidity and mortality. Autoantibodies to 11 aminoacyl-tRNA synthetases are known of which 8 have so far been associated with the clinical manifestation of ASS. The Jo-1 antibody is by far the most frequent one. The antibodies differ in the rate and severity of the main and accompanying symptoms. Treatment with selected immunosuppressive medication depends on the extent and severity of organ involvement. With a 5-year survival rate of approximately 90%, the Jo-1 syndrome has the best prognosis.

Entities:  

Keywords:  Antisynthetase antibodies; Interstitial lung disease; Jo-1; Mechanic’s hands; Polymyositis

Mesh:

Substances:

Year:  2019        PMID: 31346706     DOI: 10.1007/s00393-019-0665-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  41 in total

1.  Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.

Authors:  Miguel A González-Gay; Carlomaurizio Montecucco; Albert Selva-O'Callaghan; Ernesto Trallero-Araguas; Ovynd Molberg; Helena Andersson; Jorge Rojas-Serrano; Diana Isabel Perez-Roman; Jutta Bauhammer; Christoph Fiehn; Rossella Neri; Simone Barsotti; Hannes M Lorenz; Andrea Doria; Anna Ghirardello; Florenzo Iannone; Margherita Giannini; Franco Franceschini; Ilaria Cavazzana; Konstantinos Triantafyllias; Maurizio Benucci; Maria Infantino; Mariangela Manfredi; Fabrizio Conti; Andreas Schwarting; Giandomenico Sebastiani; Annamaria Iuliano; Giacomo Emmi; Elena Silvestri; Marcello Govoni; Carlo Alberto Scirè; Federica Furini; Francisco Javier Lopez-Longo; Julia Martínez-Barrio; Marco Sebastiani; Andreina Manfredi; Javier Bachiller-Corral; Walter Alberto Sifuentes Giraldo; Marco A Cimmino; Claudio Cosso; Alessandro Belotti Masserini; Giovanni Cagnotto; Veronica Codullo; Mariaeva Romano; Giuseppe Paolazzi; Raffaele Pellerito; Lesley Ann Saketkoo; Norberto Ortego-Centeno; Luca Quartuccio; Alberto Batticciotto; Elena Bartoloni Bocci; Roberto Gerli; Christof Specker; Elena Bravi; Carlo Selmi; Simone Parisi; Fausto Salaffi; Federica Meloni; Enrico Marchioni; Alberto Pesci; Giulia Dei; Marco Confalonieri; Paola Tomietto; Laura Nuno; Francesco Bonella; Nicolò Pipitone; Antonio Mera-Valera; Nair Perez-Gomez; Simone Gerzeli; Raquel Lopez-Mejias; Carlo Jorge Matos-Costa; Jose Antonio Pereira da Silva; José Cifrian; Claudia Alpini; Ignazio Olivieri; María Ángeles Blázquez Cañamero; Ana Belén Rodriguez Cambrón; Santos Castañeda; Lorenzo Cavagna
Journal:  Clin Exp Rheumatol       Date:  2017-07-26       Impact factor: 4.473

2.  Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.

Authors:  Cheilonda Johnson; Iago Pinal-Fernandez; Radhika Parikh; Julie Paik; Jemima Albayda; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff
Journal:  Lung       Date:  2016-05-11       Impact factor: 2.584

3.  Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system.

Authors:  M Nishikai; M Reichlin
Journal:  Arthritis Rheum       Date:  1980-08

Review 4.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome.

Authors:  Rohit Aggarwal; Namrata Dhillon; Noreen Fertig; Diane Koontz; Zengbiao Qi; Chester V Oddis
Journal:  J Rheumatol       Date:  2016-12-01       Impact factor: 4.666

6.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

7.  Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).

Authors:  Jorge Rojas-Serrano; Denisse Herrera-Bringas; Mayra Mejía; Hermes Rivero; Heidegger Mateos-Toledo; José E Figueroa
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

Review 8.  Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review.

Authors:  Michael Mahler; Frederick W Miller; Marvin J Fritzler
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

9.  Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.

Authors:  Jutta Bauhammer; Norbert Blank; Regina Max; Hanns-Martin Lorenz; Ulrich Wagner; Dietmar Krause; Christoph Fiehn
Journal:  J Rheumatol       Date:  2016-06-01       Impact factor: 4.666

10.  Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes.

Authors:  Céline Dieval; Christophe Deligny; Alain Meyer; Philippe Cluzel; Nicolas Champtiaux; Guillaume Lefevre; David Saadoun; Jean Sibilia; Jean-Luc Pellegrin; Eric Hachulla; Olivier Benveniste; Baptiste Hervier
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.